Literature DB >> 28097507

In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Els Van Peer1, Frank Jacobs2, Jan Snoeys2, Jos Van Houdt2, Ils Pijpers2, Christophe Casteleyn1, Chris Van Ginneken1, Steven Van Cruchten3.   

Abstract

PURPOSE: In view of pediatric drug development, juvenile animal studies are gaining importance. However, data on drug metabolizing capacities of juvenile animals are scarce, especially in non-rodent species. Therefore, we aimed to characterize the in vitro biotransformation of four human CYP450 substrates and one UGT substrate in the livers of developing Göttingen minipigs.
METHODS: Liver microsomes from late fetal, Day 1, Day 3, Day 7, Day 28, and adult male and female Göttingen minipigs were incubated with a cocktail of CYP450 substrates, including phenacetin, tolbutamide, dextromethorphan, and midazolam. The latter are probe substrates for human CYP1A2, CYP2C9, CYP2D6, and CYP3A4, respectively. In addition, the UGT multienzyme substrate (from the UGT-GloTM assay), which is glucuronidated by several human UGT1A and UGT2B enzymes, was also incubated with the porcine liver microsomes.
RESULTS: For all tested substrates, drug metabolism significantly rose postnatally. At one month of age, 60.5 and 75.4% of adult activities were observed for acetaminophen and dextrorphan formations, respectively, while 35.4 and 43.2% of adult activities were present for 4-OH-tolbutamide and 1'-OH-midazolam formations. Biotransformation of phenacetin was significantly higher in 28-day-old and adult females compared with males.
CONCLUSIONS: Maturation of metabolizing capacities occurred postnatally, as described in man.

Entities:  

Keywords:  CYP450; UGT; development; liver; minipig

Mesh:

Substances:

Year:  2017        PMID: 28097507     DOI: 10.1007/s11095-017-2101-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  47 in total

1.  Expression of CYP2D6 in developing human liver.

Authors:  J M Treluyer; E Jacqz-Aigrain; F Alvarez; T Cresteil
Journal:  Eur J Biochem       Date:  1991-12-05

2.  Gender-related differences in cytochrome P450 in porcine liver--implication for activity, expression and inhibition by testicular steroids.

Authors:  M K Rasmussen; G Zamaratskaia; B Ekstrand
Journal:  Reprod Domest Anim       Date:  2010-11-23       Impact factor: 2.005

3.  Analyses of CYP2C in porcine microsomes.

Authors:  Mette T Skaanild; Christian Friis
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-09-18       Impact factor: 4.080

Review 4.  The utility of the minipig as an animal model in regulatory toxicology.

Authors:  Gerd Bode; Peter Clausing; Frederic Gervais; Jeanet Loegsted; Jörg Luft; Vicente Nogues; Jennifer Sims
Journal:  J Pharmacol Toxicol Methods       Date:  2010-05-31       Impact factor: 1.950

5.  Age-related Differences in CYP3A Abundance and Activity in the Liver of the Göttingen Minipig.

Authors:  Els Van Peer; Lies De Bock; Koen Boussery; Jan Van Bocxlaer; Christophe Casteleyn; Chris Van Ginneken; Steven Van Cruchten
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-05-18       Impact factor: 4.080

6.  Sex differences in constitutive mRNA levels of CYP2B22, CYP2C33, CYP2C49, CYP3A22, CYP3A29 and CYP3A46 in the pig liver: Comparison between Meishan and Landrace pigs.

Authors:  Misaki Kojima; Masakuni Degawa
Journal:  Drug Metab Pharmacokinet       Date:  2016-02-17       Impact factor: 3.614

7.  Human cytochrome P450 maximal activities in pediatric versus adult liver.

Authors:  J G Blanco; P L Harrison; W E Evans; M V Relling
Journal:  Drug Metab Dispos       Date:  2000-04       Impact factor: 3.922

8.  Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Authors:  Nina Isoherranen; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2013-02       Impact factor: 3.922

9.  Is cytochrome P450 CYP2D activity present in pig liver?

Authors:  Mette T Skaanild; Christian Friis
Journal:  Pharmacol Toxicol       Date:  2002-10

10.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.

Authors:  C Cazeneuve; G Pons; E Rey; J M Treluyer; T Cresteil; G Thiroux; P D'Athis; G Olive
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

View more
  5 in total

1.  Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective.

Authors:  Wim Schelstraete; Laura De Clerck; Elisabeth Govaert; Joske Millecam; Mathias Devreese; Dieter Deforce; Jan Van Bocxlaer; Siska Croubels
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

Review 2.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 3.  The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development.

Authors:  Miriam Ayuso; Laura Buyssens; Marina Stroe; Allan Valenzuela; Karel Allegaert; Anne Smits; Pieter Annaert; Antonius Mulder; Sebastien Carpentier; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharmaceutics       Date:  2020-12-30       Impact factor: 6.321

4.  Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling.

Authors:  Laura Buyssens; Laura De Clerck; Wim Schelstraete; Maarten Dhaenens; Dieter Deforce; Miriam Ayuso; Chris Van Ginneken; Steven Van Cruchten
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

5.  The Ontogeny of Cytochrome P450 Enzyme Activity and Protein Abundance in Conventional Pigs in Support of Preclinical Pediatric Drug Research.

Authors:  Joske Millecam; Laura De Clerck; Elisabeth Govaert; Mathias Devreese; Elke Gasthuys; Wim Schelstraete; Dieter Deforce; Lies De Bock; Jan Van Bocxlaer; Stanislas Sys; Siska Croubels
Journal:  Front Pharmacol       Date:  2018-05-14       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.